Myocardial injury in hospitalized patients with COVID-19 infection-Risk factors and outcomes.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
09
2020
accepted:
14
02
2021
entrez:
26
2
2021
pubmed:
27
2
2021
medline:
10
3
2021
Statut:
epublish
Résumé
Myocardial injury in hospitalized patients is associated with poor prognosis. This study aimed to evaluate risk factors for myocardial injury in hospitalized patients with coronavirus disease 2019 (COVID-19) and its prognostic value. We retrieved all consecutive patients who were hospitalized in internal medicine departments in a tertiary medical center from February 9th, 2020 to August 28th with a diagnosis of COVID-19. A total of 559 adult patients were hospitalized in the Sheba Medical Center with a diagnosis of COVID-19, 320 (57.24%) of whom were tested for troponin levels within 24-hours of admission, and 91 (28.44%) had elevated levels. Predictors for elevated troponin levels were age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.01-1.06), female sex (OR, 3.03; 95% CI 1.54-6.25), low systolic blood pressure (OR, 5.91; 95% CI 2.42-14.44) and increased creatinine level (OR, 2.88; 95% CI 1.44-5.73). The risk for death (hazard ratio [HR] 4.32, 95% CI 2.08-8.99) and a composite outcome of invasive ventilation support and death (HR 1.96, 95% CI 1.15-3.37) was significantly higher among patients who had elevated troponin levels. In conclusion, in hospitalized patients with COVID-19, elevated troponin levels are associated with poor prognosis. Hence, troponin levels may be used as an additional tool for risk stratification and a decision guide in patients hospitalized with COVID-19.
Identifiants
pubmed: 33635914
doi: 10.1371/journal.pone.0247800
pii: PONE-D-20-29899
pmc: PMC7909655
doi:
Substances chimiques
Troponin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0247800Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Am Coll Cardiol. 2020 Aug 4;76(5):533-546
pubmed: 32517963
Circulation. 2021 Feb 9;143(6):553-565
pubmed: 33186055
JAMA Cardiol. 2020 Nov 1;5(11):1265-1273
pubmed: 32730619
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
Circulation. 2020 Jul 7;142(1):68-78
pubmed: 32293910
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
JAMA Cardiol. 2020 Nov 1;5(11):1281-1285
pubmed: 32730555
Sci Rep. 2020 Dec 10;10(1):21619
pubmed: 33303788
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA Cardiol. 2020 Nov 1;5(11):1274-1280
pubmed: 32845276
Heart Rhythm. 2020 Sep;17(9):1439-1444
pubmed: 32585191
Circulation. 2020 Sep 15;142(11):1123-1125
pubmed: 32689809
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Am J Cardiol. 2015 Aug 15;116(4):647-51
pubmed: 26089009
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Medicine (Baltimore). 2009 May;88(3):154-159
pubmed: 19440118
SN Compr Clin Med. 2020 Aug 14;:1-6
pubmed: 32838188
Lancet. 2013 Feb 9;381(9865):496-505
pubmed: 23332146
JAMA Cardiol. 2020 Jul 1;5(7):831-840
pubmed: 32219363
J Clin Med. 2020 Oct 12;9(10):
pubmed: 33053826
PLoS Med. 2011 Jun;8(6):e1001048
pubmed: 21738449
J Med Virol. 2020 Jul;92(7):819-823
pubmed: 32232979